Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BridgeBio Pharma, Inc. (BBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $68,30, with a market capitalisation of $14,15B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $48,78 to $93,42. This page covers its latest market performance, valuation, price trends and company information.
$14,15B | |
$68,40 | |
$93,42 | |
$4,98 | |
$68,39 | |
393,00 | |
3,05M | |
-- | |
$93,42 | |
$48,78 | |
-- | |
-- |
BridgeBio Pharma, Inc. (BBIO) is trading at $68,30 in pre-market trading as of 2026-09-16 08:56:00, down 0,13% ($0,09) from the previous close of $68,39
Pre-market trading shows how investors are pricing BBIO before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, BridgeBio Pharma, Inc. (BBIO) moved from $74,84 to $68,30, representing a decline of 8,74% ($6,54).
The stock traded between $66,96 and $76,81 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,37 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 43,7%
BBIO is currently trading at $68,30, placing it 43,7% of the way from its 52-week low of $48,78 to its 52-week high of $93,42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 839 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BridgeBio Pharma, Inc. (BBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.